- Home
- PALI vs PRQR Comparison
PALI vs PRQR Comparison
Compare PALI & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | PRQR |
|---|---|---|
| Founded | 1996 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.8M | 250.7M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | PALI | PRQR |
|---|---|---|
| Price | $2.49 | $1.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $17.67 | $8.14 |
| AVG Volume (30 Days) | ★ 5.8M | 649.8K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $18,859,556.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.53 | $1.07 |
| 52 Week High | $2.64 | $3.10 |
Technical Indicators
Market Signals| Indicator | PALI | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 42.43 |
| Support Level | $2.24 | $1.91 |
| Resistance Level | $2.64 | $2.31 |
| Average True Range (ATR) | 0.18 | 0.15 |
| MACD | 0.06 | -0.02 |
| Stochastic Oscillator | 89.39 | 18.09 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.